Shanghai Junshi Biosciences Co., Ltd.SSE: 688180

(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Acceptance of the Marketing Application for Toripalimab Injection (Subcutaneous Injection) for a New Indication in First-line Treatment of HER2-Expressing Urothelial Carcinoma

· Issued by Shanghai Junshi Biosciences Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688180 ·

On 6ix: 6ix.com/news/688180shanghai-junshi-biosciences-co-ltdannouncement-on-voluntary-disclosure-of-the-acceptance-of-the-marketing-application-for-toripalimab-injection-subcutaneous-injection-for-a-new-indication-in-first-line-treatment-of-her2-expressing-urothelial-carcinoma

Announcement on Voluntary Disclosure of the Acceptance of the Marketing Application for Toripalimab Injection (Subcutaneous Injection) for a New Indication in First-line Treatment of HER2-Expressing Urothelial Carcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Shanghai Junshi Biosciences Co., Ltd. on 6ix

Story so far

Earlier from Shanghai Junshi Biosciences

Later from Shanghai Junshi Biosciences

All Shanghai Junshi Biosciences news releases